SEARCH:   Advanced

Blood, 15 April 2007, Vol. 109, No. 8, pp. 3393-3399. Prepublished online as a Blood First Edition Paper on December 12, 2006; DOI 10.1182/blood-2006-07-030593. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-07-030593v1 109/8/3393    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kanter, G. Articles by Levy, R. Search for Related Content PubMed PubMed Citation Articles by Kanter, G. Articles by Levy, R. Related Collections Immunotherapy Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines Gregory Kanter1, Junhao Yang2, Alexei Voloshin2, Shoshana Levy1, James R. Swartz2,3, and Ronald Levy1 1 Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, CA; 2 Department of Chemical Engineering, Stanford University, Stanford, CA; 3 Department of Bioengineering, Stanford University, Stanford, CA The unique immunoglobulin (Ig) idiotype on the surface of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a therapeutic vaccine. We have used an Escherichia coli—based, cell-free protein-expression system to produce a vaccine within hours of cloning the Ig genes from a B-cell tumor. We demonstrated that a fusion protein consisting of an idiotypic single chain Fv antibody fragment (scFv) linked to a cytokine (GM-CSF) or to an immunostimulatory peptide was an effective lymphoma vaccine. These vaccines elicited humoral immune responses against the native Ig protein displayed on the surface of a tumor and protected mice against tumor challenge with efficacy equal to that of the conventional Ig produced in a mammalian cell and chemically coupled to keyhole limpet hemocyanin. The cell-free E coli system offers a platform for rapidly generating individualized vaccines, thereby allowing much more efficient application in the clinic. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020